Publicaciones en colaboración con investigadores/as de Universitat de València (15)

2024

  1. Dispersal history of SARS-CoV-2 in Galicia, Spain

    Journal of Medical Virology, Vol. 96, Núm. 7

  2. Mohs micrographic surgery in immunosuppressed vs immunocompetent patients: Results of a prospective nationwide cohort study (REGESMOHS, Spanish registry of Mohs surgery)

    Journal of the European Academy of Dermatology and Venereology

  3. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy

    Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806

  4. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  5. Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study

    International Journal of Dermatology

2023

  1. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2021

  1. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

    American Journal of Gastroenterology, Vol. 116, Núm. 11, pp. 2250-2257

  2. Primary cutaneous lymphomas in children: A prospective study from the Spanish Academy of Dermatology and Venereology (AEDV) Primary Cutaneous Lymphoma Registry

    Pediatric Dermatology, Vol. 38, Núm. 6, pp. 1506-1509

2019

  1. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

2016

  1. Factors associated with fatality during the intensive phase of anti-tuberculosis treatment

    PLoS ONE, Vol. 11, Núm. 8

2014

  1. Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients

    Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, Vol. 38, Núm. 5, pp. 418-429

2012

  1. A predictive scoring instrument for tuberculosis lost to follow-up outcome

    Respiratory Research, Vol. 13